PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials

Abstract Background Ovarian cancer is the eighth leading cause of cancer-related death among women, characterized by late diagnosis and a high relapse rate. In randomized controlled trials, we aimed to evaluate the efficacy and safety of PARP inhibitors (PARPi) in treating advanced ovarian cancer. M...

ver descrição completa

Detalhes bibliográficos

Principais autores:	István Baradács, Brigitta Teutsch, Alex Váradi, Alexandra Bilá, Ádám Vincze, Péter Hegyi, Tamás Fazekas, Balázs Komoróczy, Péter Nyirády, Nándor Ács, Ferenc Bánhidy, Balázs Lintner
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2024-02-01
coleção:	Journal of Ovarian Research
Assuntos:	Olaparib Niraparib Rucaparib HRD Homologous recombination repair
Acesso em linha:	https://doi.org/10.1186/s13048-024-01362-y
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!